Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Conditions
- Advanced Malignant Solid NeoplasmClinical Stage III Cutaneous Melanoma AJCC V8Clinical Stage IV Cutaneous Melanoma AJCC V8Fallopian Tube CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic MelanomaMetastatic Renal Cell CarcinomaOvarian CarcinomaPathologic Stage III Cutaneous Melanoma AJCC V8
- Interventions
- Drug: CarboplatinDrug: EribulinDrug: FluorouracilDrug: PaclitaxelDrug: CyclophosphamideDrug: CapecitabineBiological: PembrolizumabDrug: OlaparibBiological: NivolumabBiological: IpilimumabDrug: SelinexorDrug: DoxorubicinDrug: TopotecanDrug: PemetrexedDrug: Irinotecan HydrochlorideDrug: OxaliplatinDrug: Leucovorin Calcium
- First Posted Date
- 2015-04-17
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 221
- Registration Number
- NCT02419495
- Locations
- 🇺🇸
MD Anderson in The Woodlands, Conroe, Texas, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸MD Anderson West Houston, Houston, Texas, United States
DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2015-04-14
- Last Posted Date
- 2015-04-14
- Lead Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
- Target Recruit Count
- 100
- Registration Number
- NCT02415699
Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer
- Conditions
- Stage IVB Colorectal CancerColorectal AdenocarcinomaStage IVA Colorectal Cancer
- Interventions
- Drug: CBP/beta-catenin Antagonist PRI-724Biological: BevacizumabDrug: Leucovorin CalciumDrug: OxaliplatinDrug: FluorouracilOther: Laboratory Biomarker Analysis
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2017-04-17
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT02413853
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2015-04-10
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Target Recruit Count
- 82
- Registration Number
- NCT02414009
- Locations
- 🇮🇹
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Mi, Italy
Molecular Phenotyping in Predicting Response in Patients With Stage IB-III Esophageal Cancer Receiving Combination Chemotherapy
- Conditions
- Stage IB Esophageal AdenocarcinomaStage IIA Esophageal AdenocarcinomaStage IIB Esophageal AdenocarcinomaStage IIIA Esophageal AdenocarcinomaStage IIIB Esophageal AdenocarcinomaStage IIIC Esophageal Adenocarcinoma
- Interventions
- Drug: PaclitaxelDrug: OxaliplatinDrug: Leucovorin CalciumDrug: CarboplatinRadiation: Radiation TherapyDrug: FluorouracilProcedure: Therapeutic Conventional SurgeryOther: Laboratory Biomarker Analysis
- First Posted Date
- 2015-03-19
- Last Posted Date
- 2018-02-13
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT02392377
- Locations
- 🇺🇸
Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2022-05-13
- Lead Sponsor
- Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 243
- Registration Number
- NCT02383966
- Locations
- 🇩🇪
Research site, Darmstadt, Germany
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Neoplasm
- Interventions
- First Posted Date
- 2015-03-10
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- GSO Global Clinical Research BV
- Target Recruit Count
- 10
- Registration Number
- NCT02384850
- Locations
- 🇧🇪
University Hospital Antwerpen, Antwerpen, Belgium
🇩🇪University Hospital Hamburg, Hamburg, Germany
Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients
- Conditions
- Colorectal Carcinoma
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2015-03-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT02376452
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
Effects of Deep Regional Hyperthermia in Patients With Anal Carcinoma Treated by Standard Radiochemotherapy
- Conditions
- Anal Carcinoma
- Interventions
- First Posted Date
- 2015-02-24
- Last Posted Date
- 2017-08-11
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 118
- Registration Number
- NCT02369939
- Locations
- 🇩🇪
Universitaetsklinikum Erlangen, Strahlenklinik, Erlangen, Germany
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
- Conditions
- Stage IIIA Esophageal AdenocarcinomaEsophageal AdenocarcinomaStage IIIC Gastric CancerGastric AdenocarcinomaStage IIIB Esophageal AdenocarcinomaStage IIIC Esophageal AdenocarcinomaStage IIB Gastric CancerStage IIIB Gastric CancerStage IIIA Gastric Cancer
- Interventions
- Drug: OxaliplatinDrug: Leucovorin CalciumDrug: Irinotecan HydrochlorideDrug: FluorouracilProcedure: Conventional Surgery
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 36
- Registration Number
- NCT02366819
- Locations
- 🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Kellogg Cancer Center - Evanston Hospital, Evanston, Illinois, United States
🇺🇸NorthShore University HealthSystem, Evanston, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.